HIV-1 integrase: the next target for AIDS therapy?

Area of Science:

• Biochemistry and Molecular Biology
• Virology
• Medicinal Chemistry

Background:

• Acquired Immunodeficiency Syndrome (AIDS) is caused by Human Immunodeficiency Virus type 1 (HIV-1).
• Current HIV-1 treatments involve combination therapy with reverse transcriptase and protease inhibitors.
• HIV-1 integrase (IN) is a critical enzyme for viral DNA integration and an emerging drug target.

Purpose of the Study:

• To develop novel inhibitors targeting the catalytic core domain of HIV-1 IN.
• To investigate the potential of polyhydroxylated styrylquinolines as HIV-1 IN inhibitors.
• To evaluate the efficacy and safety of these compounds in blocking HIV-1 replication.

Main Methods:

• Development and synthesis of novel polyhydroxylated styrylquinolines.
• Assay of HIV-1 IN inhibitory activity and cytotoxicity.
• Analysis of crystal structures of HIV-1 IN catalytic core domain and inhibitor complexes.
• Molecular dynamics simulations to understand enzyme-inhibitor interactions.

Main Results:

• Polyhydroxylated styrylquinolines demonstrated potent submicromolar inhibition of HIV-1 IN.
• These compounds effectively blocked HIV-1 replication in cell culture with no observed cytotoxicity.
• Structural studies revealed inhibitor binding within the active site, involving key amino acid residues and potential metal ion coordination.

Conclusions:

• Polyhydroxylated styrylquinolines are effective inhibitors of HIV-1 IN, offering a new therapeutic avenue.
• The findings support the hypothesis that HIV-1 IN inhibitors function via metal ion chelation.
• HIV-1 IN represents a viable target for rational drug design, potentially for use in combination regimens.